Impact of Early Tumour Shrinkage on Long-term Outcome In Metastatic Colorectal Cancer (mCRC) Treated With 5FU+Irinotecan plus Leucovorin (FOLFIRI) or Capecitabine plus Irinotecan XELIRI Plus Bevacizumab

被引：3
|
作者：
Ichante, J. L. [1 ]
Adenis, A. [2 ]
Francois, E. [3 ]
Boucher, E. [4 ]
Pignon, J. P. [1 ]
Ychou, M. [5 ]
Pierga, J. Y. [6 ]
Montotot-Grillo, C. [7 ]
Conroy, T. [8 ]
Ducreux, M. [1 ]
机构：
[1] Inst Gustave Roussy, Villejuif, France
[2] Ctr Oscar Lambret, F-59020 Lille, France
[3] Ctr Antoine Lacassagne, F-06054 Nice, France
[4] Ctr Eugene Marquis, Rennes, France
[5] Ctr Val Aurelle, Montpellier, France
[6] Inst Curie, Paris, France
[7] Federat Ctr Lutte Canc, Paris, France
[8] Ctr Alexis Vautrin, Nancy, France
来源：
EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷
关键词：
D O I：
10.1016/S0959-8049(11)71739-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S419 / S419
页数：1
相关论文
共 50 条
  • [21] FOLFOX/bevacizumab plus /- irinotecan in advanced colorectal cancer (CHARTA): Long term outcome
    Schmoll, H.
    Garlipp, B.
    Junghanss, C.
    Vogel, A.
    Kaiser, U.
    Florschuetz, A.
    Kanzler, S.
    Hannig, C.
    Meinert, F.
    Cygon, F.
    Stein, A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [22] Capecitabine plus irinotecan in combination with bevacizumab in chemonaive metastatic colorectal cancer, pilot study
    Kocakova, I
    Lakomy, R.
    Spelda, S.
    Kocak, I
    Vyzula, R.
    ANNALS OF ONCOLOGY, 2006, 17 : 41 - 41
  • [23] Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial
    Erik Skof
    Martina Rebersek
    Zvezdana Hlebanja
    Janja Ocvirk
    BMC Cancer, 9
  • [24] First-line treatment with infusional 5-FU, leucovorin, and irinotecan plus bevacizumab (FOLFIRI-B) for metastatic colorectal cancer (MCRC): Preliminary results of a phase II trial
    Kopetz, S.
    Glover, K.
    Eng, C.
    Adinin, R.
    Morris, J.
    Wolff, R.
    Lin, E.
    Chang, D.
    Abbruzzese, J.
    Hoff, P.
    ANNALS OF ONCOLOGY, 2006, 17 : 73 - 73
  • [25] Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial
    Skof, Erik
    Rebersek, Martina
    Hlebanja, Zvezdana
    Ocvirk, Janja
    BMC CANCER, 2009, 9
  • [26] A comparison of efficacy of first-line chemotherapy regimens for metastatic colorectal cancer (mCRC): FOLFIRI plus bevacizumab vs. XELIRI plus bevacizumab
    Ocvirk, J.
    Rebersek, M.
    Boc, M.
    EJC SUPPLEMENTS, 2009, 7 (02): : 336 - 336
  • [27] Impact of bevacizumab plus 5-FU/LV with or without irinotecan on quality of life in patients with metastatic colorectal cancer
    Chawla, A.
    Holmgren, E.
    Nelson, B.
    Cella, D.
    Yost, K.
    Hurwitz, H.
    Kabbinavar, F.
    Novotny, W.
    Mrad, R.
    EJC SUPPLEMENTS, 2005, 3 (02): : 367 - 367
  • [28] Bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as the second-line therapy for patients with metastatic colorectal cancer, a multicenter study
    Ting Deng
    Le Zhang
    Xiao-jian Liu
    Jian-ming Xu
    Yu-xian Bai
    Yan Wang
    Yu Han
    Yu-hong Li
    Yi Ba
    Medical Oncology, 2013, 30
  • [29] Bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as the second-line therapy for patients with metastatic colorectal cancer, a multicenter study
    Deng, Ting
    Zhang, Le
    Liu, Xiao-jian
    Xu, Jian-ming
    Bai, Yu-xian
    Wang, Yan
    Han, Yu
    Li, Yu-hong
    Ba, Yi
    MEDICAL ONCOLOGY, 2013, 30 (04)
  • [30] Efficacy of bevacizumab plus bolus irinotecan, fluorouracil and leucovorin (IFL-BV) for highly pretreated metastatic colorectal cancer (MCRC)
    Carrera, S.
    Munoz, A.
    Gil-Negrete, A.
    Rubio, I
    Ancizar, N.
    Calvo, B.
    Fuente, N.
    Barcelo, R.
    Janhi, M.
    Lopez-Vivanco, G.
    ANNALS OF ONCOLOGY, 2006, 17 : 68 - 68
12345